Please assess the completion status of the following clinical trial:

Trial Title: RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of an advanced, malignant, solid tumor(s) with all standard treatment options having been exhausted or declined.~* Eastern Cooperative Group (ECOG) performance status is 0-2 at Screening.~* Measurable disease per RECIST v1.1 by radiographic techniques~* Acceptable liver function, serum creatinine and hematological status~* Female subjects of childbearing potential, and male subjects with partners of childbearing potential, must agree to use medically acceptable methods of contraception beginning on Study Day 1 and continuing until at least four weeks after administration of the subject's final dose of RRx-001.~* Subjects with brain metastases are eligible~Exclusion Criteria:~* Concurrent anticancer therapy; however, radiotherapy is allowed~* Any history of hypersensitivity to irinotecan~* Cholangitis that required treatment or intervention within 4 weeks of study enrollment~* Bilirubin \> 2.0 mg/dL~* Serious medical or psychiatric illness likely to interfere with participation in this clinical study~* If female, subject is pregnant and/or breastfeeding.~* UGT1A1\*28 homozygote or heterozygote~* BMI \>35

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RRx-001 + Irinotecan (Type: EXPERIMENTAL): Cohorts of participants with an advanced, malignant, solid tumor(s) will receive weekly doses of RRx-001 for 3 weeks, switching at week 4 to every-other-week treatments of RRx-001 with irinotecan.

Based on this trial design, predict the completion outcome and termination type (if applicable).